Ad
related to: zyprexa withdrawal effects medication interactions symptoms list of approvedgoodrx.com has been visited by 100K+ users in the past month
This free app will find the best local deals. - AOL.com
Search results
Results from the WOW.Com Content Network
Adverse effects that threaten serious harm, aggravate other medical conditions, or make a person want to stop taking their medications are all examples of drug intolerance. Certain drug interactions can cause adverse effects as well. [1] Patient/guardian preference: A patient or caregiver may prefer a different antipsychotic. This may be due to ...
Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating. [ 1 ] Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either ...
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. [13] It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting [14] and as an appetite stimulant. [15]
Very common adverse effects of olanzapine, occurring more than 10%, include: Weight gain (dose-dependent). Weight gain of over 7% of a person's initial body weight prior to treatment is in this category of very common too with some estimates of its incidence putting it at around 40.6%.
This technique may be used if your medication puts you at risk for withdrawal symptoms, which may occur when some antidepressants are stopped without a gradual taper. Taper and moderate switch.
In the new research, the most commonly used antidepressants in the UK were found to have the lowest rates of withdrawal symptoms throughout the study. Antidepressants: New study sheds light on ...
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed